CTSO

CytoSorbents is a real, revenue-generating blood-purification business, not a concept stock: CytoSorb is CE-marked, sold in 70+ countries with 300,000+ devices used cumulatively, and carries a healthy 71.5% gross margin (up from 69.9%). The operating trajectory is genuinely improving — net loss narrowed from -$32.8M (FY2022) to -$8.2M (FY2025), a 60.4% YoY improvement, and operating loss improved 10.4% to -$14.7M on +4.1% revenue growth to $37.1M. At a 0.7x P/S and a $24.5M market cap, the equity is optically cheap for a 71% gross-margin medical-device franchise.

The problem is the balance sheet and the funding gap, which dominate everything else. The 10-K states FY2025 cash burn (operating + investing) was ~$12.8M against only $6.25M cash and equivalents ($7.8M including $1.5M restricted) — well under one year of runway. Stockholders' equity fell 46.9% to $5.9M against $38.3M of liabilities (6.48x), long-term debt rose 19.1% to $16.7M, and operating cash flow was -$12.4M. Management is explicit that it 'may require additional financing' and has an effective $150M shelf ($149.7M available) plus a $20M ATM already tapped via a 2025 rights offering and warrant exercises. With a $24.5M cap and a $0.39 share price, closing that gap means heavy, near-certain dilution to existing holders — a structural overhang that caps upside even if the business keeps improving.